Malignant News and Research

RSS

World’s first Cesium-131 implant for recurrent head and neck cancer performed

IsoRay, Inc. (Amex: ISR) announced today that on August 5, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, Dr. David Kutler of the Department of Otorhinolaryngology, and Dr. Jason Spector of the Department of Plastic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 implant for a recurrent head and neck cancer (buccal mucosa).

28 Sep 2009

Research study supports reovirus and cisplatin combination for cancer treatment

Oncolytics Biotech Inc. ('Oncolytics') reported today that research led by Prof. Hardev Pandha of the Royal Surrey County Hospital, U.K., was published September 22, 2009 in the online version of Clinical Cancer Research.

25 Sep 2009

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.

24 Sep 2009

New method found for the treatment of pancreatic cancer

For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

24 Sep 2009

Hsp-27 protein: An indicator of prostate cancer progression

In the largest study of its kind, the international team of pathologists studied an initial 4,000 prostate cancer patients over a period of 15 years to further understanding into the natural progression of the disease and how it should be managed. The research, published in the British Journal of Cancer, could be used to develop a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.

24 Sep 2009

Lab-on-a-chip performs 1,000 chemical reactions at once

Flasks, beakers, and hot plates may soon be a thing of the past in medicinal chemistry labs. Instead of handling a few experiments on a benchtop, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results literally shrinking the lab down to the size of a thumbnail.

From Siemens Healthineers 23 Sep 2009

Titanium dioxide nanoparticles catalyze brain tumor death

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago Medical Center's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to antibodies.

23 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

ESMO recognises outstanding achievements of leading cancer specialists

The European Society for Medical Oncology (ESMO) has recognized the outstanding achievements of three leading cancer specialists with its three prestigious annual awards: the 2009 ESMO Award, Hamilton Fairley Award and ESMO Lifetime Achievement Award.

23 Sep 2009

Advancements in the treatment of metastatic malignant melanoma

23 Sep 2009

There is no evidence to support the use of any test for ovarian cancer: NBOCC

In an Australian first, leading experts and organizations have agreed a position statement on screening for ovarian cancer, Australia's leading cause of death from gynecological malignancy.

23 Sep 2009

Private cord blood banking can treat medical conditions but is expensive

Private cord blood banking is not cost-effective because it costs an additional $1,374,246 per life-year gained, according to a new analysis by UCSF researchers. The research team also concluded that private cord blood banking is cost-effective only for families with a child with a very high likelihood of needing a stem cell transplant.

23 Sep 2009

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

22 Sep 2009

Research to study how eukaryotic cells help in building proteins

Federal stimulus funding is helping a Kansas State University biologist continue to collaborate with the Harvard Medical School. Their research is creating a clearer picture of a certain cellular process that can play a role in chronic diseases like cancer.

22 Sep 2009

MRS could be effective for identifying diabetes

Researchers have long suspected that overweight people tend to have large fat deposits in their pancreases, but they've been unable to confirm or calculate how much fat resides there because of the organ's location.

22 Sep 2009

Patients with higher levels of vitamin D are less likely to die from skin cancer

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Differences between two types of integrins

The adhesion of cells to the various components of their environment is mediated mainly by molecules known as integrins. Two integrins, α5β1 and αvβ3, mediate adhesion with fibronectin, which is present in the extracellular matrix. But why are 2 molecules involved in the adhesion to a single extracellular component? An article published on-line in Proceedings of the National Academy of Sciences (PNAS), whose main author is Pere Roca-Cusachs, an IBEC researcher, offers the first experimental answer to this question.

21 Sep 2009